Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis

Clinical Research in Cardiology

Volumn 104, Issue 5, 2015, Pages 418-429

  Nielsen, Peter Brønnum ^a,b   Lane, Deirdre A ^c   Rasmussen, Lars Hvilsted ^a,b   Lip, Gregory Y H ^b,c   Larsen, Torben Bjerregaard ^a,b  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Atrial fibrillation; Efficacy; Meta analysis; Oral anticoagulants; Renal function; Safety

Indexed keywords

ANTICOAGULANT AGENT; VITAMIN K GROUP; WARFARIN;

ANTAGONISTS AND INHIBITORS; ATRIAL FIBRILLATION; BLEEDING; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); HUMAN; META ANALYSIS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL INSUFFICIENCY; STROKE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; HEMORRHAGE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY; STROKE; TREATMENT OUTCOME; VITAMIN K; WARFARIN;

EID: 84934277855     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-014-0797-9     Document Type: Article

References (41)

1. Soliman EZ, Prineas RJ, Go AS et al (2010) Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 159:1102–1107. doi:10.1016/j.ahj.2010.03.027
2. Alonso A, Lopez FL, Matsushita K et al (2011) Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 123:2946–2953. doi:10.1161/CIRCULATIONAHA.111.020982
3. Hart RG, Pearce LA, Asinger RW, Herzog CA (2011) Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol 6:2599–2604. doi:10.2215/CJN.02400311
4. Olesen JB, Lip GYH, Kamper A-L et al (2012) Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 367:625–635. doi:10.1056/NEJMoa1105594
5. Marinigh R, Lane DA, Lip GYH (2011) Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 57:1339–1348. doi:10.1016/j.jacc.2010.12.013
6. Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151. doi:10.1056/NEJMoa0905561
7. Patel MR, Mahaffey WK, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891. doi:10.1016/S0019-4832(12)60029-7
8. Granger CB, Alexander JH, McMurray JJV et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992. doi:10.1056/NEJMoa1107039
9. Giugliano RP, Ruff CT, Braunwald E et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093–2104. doi:10.1056/NEJMoa1310907
10. Stangier J, Rathgen K, Stähle H, Mazur D (2010) Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 49:259–268. doi:10.2165/11318170-000000000-00000
11. Blech S, Ebner T, Ludwig-Schwellinger E et al (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36:386–399. doi:10.1124/dmd.107.019083
12. Frost C, Wang J, Nepal S et al (2013) Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 75:476–487. doi:10.1111/j.1365-2125.2012.04369.x
13. Weitz JI, Connolly SJ, Patel I et al (2010) Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 104:633–641. doi:10.1160/TH10-01-0066
14. Weinz C, Schwarz T, Kubitza D et al (2009) Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 37:1056–1064. doi:10.1124/dmd.108.025569
15. Heidbuchel H, Verhamme P, Alings M et al (2013) European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 15:625–651. doi:10.1093/europace/eut083
16. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62:1006–1012. doi:10.1016/j.jclinepi.2009.06.005
17. The Cochrane Collaboration (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. http://handbook.cochrane.org/. Accessed 5 Aug 2013
18. Harbord RM, Higgins JPT (2008) Meta-regression in Stata. Stata J 8:493–519
19. Bucher HC, Guyatt GH, Griffith LE, Walter SD (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50:683–691. doi:10.1016/S0895-4356(97)00049-8
20. White IR (2009) Multivariate random-effects meta-analysis. Stata J 9:40–56
21. Bagos PG (2012) On the covariance of two correlated log-odds ratios. Stat Med 31:1418–1431. doi:10.1002/sim.4474
22. Ezekowitz MD, Reilly PA, Nehmiz G et al (2007) Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 100:1419–1426
23. Hori M, Matsumoto M, Tanahashi N et al (2012) Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation—the J-ROCKET AF study. Circ J 76:2104–2111. doi:10.1253/circj.CJ-12-0454
24. Ogawa S, Shinohara Y, Kanmuri K (2011) Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation—the ARISTOTLE-J study. Circ J 75:1852–1859. doi:10.1253/circj.CJ-10-1183
25. Gallagher AM, Setakis E, Plumb JM et al (2011) Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 106:968–977. doi:10.1160/TH11-05-0353
26. Gallego P, Roldan V, Marín F et al (2013) Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 110:1189–1198. doi:10.1160/TH13-07-0556
27. De Caterina R, Husted S, Wallentin L et al (2013) General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost 109:569–579. doi:10.1160/TH12-10-0772
28. De Caterina R, Husted S, Wallentin L et al (2013) Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position Paper of the ESC Working Group on Thrombosis—Task Force on Anticoagulants in Heart Disease. Thromb Haemost 110:1087–1107. doi:10.1160/TH13-06-0443
29. Limdi NA, Limdi MA, Cavallari L et al (2010) Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis 56:823–831. doi:10.1053/j.ajkd.2010.05.023
30. Hohnloser SH, Hijazi Z, Thomas L et al (2012) Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 33:2821–2830. doi:10.1093/eurheartj/ehs274
31. Huisman MV, Lip GYH, Diener H-C et al (2012) Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 107:838–847. doi:10.1160/TH11-10-0718
32. Rasmussen LH, Larsen TB, Graungaard T et al (2012) Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. BMJ 345:e7097. doi:10.1136/bmj.e7097
33. Lip GYH, Larsen TB, Skjøth F, Rasmussen LH (2012) Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol 60:738–746. doi:10.1016/j.jacc.2012.03.019
34. Larsen TB, Lip GYH (2014) Warfarin or novel oral anticoagulants for atrial fibrillation? Lancet 383:931–933. doi:10.1016/S0140-6736(13)62376-4
35. Skjøth F, Larsen TB, Rasmussen LH (2012) Indirect comparison studies—are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillation. Thromb Haemost 108:1–2. doi:10.1160/TH12-06-0438
36. Ruff CT, Giugliano RP, Braunwald E et al (2013) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. doi:10.1016/S0140-6736(13)62343-0
37. Harel Z, Sholzberg M, Shah PS et al (2014) Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD. J Am Soc Nephrol 25:431–442. doi:10.1093/eurheartj/ehr342
38. Camm AJ, Lip GYH, De Caterina R et al (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation—developed with the special contribution of the European Heart Rhythm Association. Europace 14:1385–1413. doi:10.1093/europace/eus305
39. Roldán V, Marín F, Fernández H et al (2013) Renal impairment in a “real-life” cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol 111:1159–1164. doi:10.1016/j.amjcard.2012.12.045
40. Fox KA, Piccini JP, Wojdyla D et al (2011) Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 32:2387–2394. doi:10.1093/eurheartj/ehr342
41. Hori M, Matsumoto M, Tanahashi N et al (2013) Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment. Circ J 77:632–638. doi:10.1253/circj.CJ-12-0899